An Observational Post-Authorization Safety Surveillance (PASS) Study of SYCREST® (asenapine) among Patients aged 18 and older Diagnosed with Bipolar Disorder (P08307)

24/05/2017
02/07/2024
EU PAS number:
EUPAS17631
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

8274-110+Protocol_final-redaction

English (4.96 MB - PDF) View document
Study results
Study results

MK-8274-110_final-report_NoAppendices_final-redaction

English (2.85 MB - PDF) View document
Study report
Other information